tbuckley/cabot-search huggingface dataset:
AB0918 Prevalence of Previous Pfapa Syndrome in Behcet's Disease
Authors: P. Ene, L. Damian, A. Maniu, O. Serban, S.-P. Simon, S. Rednic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Marshall9s syndrome or PFAPA (periodic fever, aphtous stomatitis, pharyngitis, cervical adenitis) is a pediatric diseases characterized by recurrent febrile episodes associtaed with head and neck symptoms, improved or cured after tonsillectomy. Differential diagnosis includes infectious angina, Behcet9s disease, cyclic neutropenia, TRAPS syndrome and other autoinflammatory syndromes. However, part of the patients with Behcet9s disease may have PFAPA as part of their disease onset. <h3>Objectives</h3> We aimed to investigate the reported prevalence of PFAPA symptoms in patients with Behcet9s disease. <h3>Methods</h3> The patients in the evidence of the Rheumatology Dept, a tertiary referral unit, with confirmed Behcet9s syndrome (according to ISSG) presenting in the last year, were taken into the cross-sectional study, after informed consent. A questionnaire (AMAB) was developed and employed, with regard to the presence of diagnostic Marshall/ PFAPA features (Thomas 1998), familial history, tonsillectomy, fever presence and pattern and other possible features of BD appearing in childhood. Cyclic neutropenia was ruled out as part of clinical investigations, and data regarded the pathergy, eye examination and thrombotic events were obtained from the medical records. <h3>Results</h3> We enrolled 21 patients (11 F, 12 M), average age 47.6 yrs, that agreed to answer the questionnaire. In the whole responder BD group, fever was present in 38.1%. We found that 23% of the responder BD patients reported symptoms compatible with a PFAPA diagnosis, with a medium age of onset of 8.2 years. BD was diagnosed at 40±12.8 yrs (15–56), but in the patients with PFAPA symptoms the onset was earlier (28±12.3 yrs). In the 3 patients with tonsillectomy, the symptoms improved for several years, only to reappear milder after adolescence, along with other features of BD. Most patients (76.19%) recalled ulcers since childhood, and isolated oral ulcers generally remained as such until occurrence of other diagnostic BD features. We found no differences in the severity of the disease, eye involvement or thrombosis prevalence in the patients with or without PFAPA features. <h3>Conclusions</h3> PFAPA may co-exist as an associated disease in BD and is not necessarily an exclusion diagnosis. Although many patients with BD suffer from oral ulcers since childhood, BD symptoms appear in most after adolescence. <h3>References</h3> International Study Group for Behcet9s disease. Criteria for diagnosis of Behcet9s disease. Lancet 1990; 5:335(8697):1078–80. Cantarini L, Vitale A, Bersani G, Nieves LM et al: PFAPA syndrome and Behcet9s disease: a comparison of the two medical entities based on the clinical interviews performed by three different specialists. Clin Rheumatol 2015 Feb 10. <h3>Disclosure of Interest</h3> None declared
Abstract 2228: Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells
Authors: Manabu Seino, Masashi Okada, Keita Shibuya, Shizuka Seino, Shuhei Suzuki, Hiroyuki Takeda, Tsuyoshi Ohta, Hirohisa Kurachi, Kiyoshi Ito, Satoru Nagase, Chifumi Kitanaka
Journal: Cancer Research (2015)

Abstract Background/Aim: Activation of the c-JUN N-terminal kinase (JNK) signaling pathway has been associated with poor survival of patients with ovarian cancer, but the role(s) and significance of JNK signaling in ovarian cancer cells remain poorly understood. Here in this study, we aimed to investigate the role of JNK specifically in ovarian cancer stem cells (CSCs). Materials and Methods: The effect of JNK inhibition on the self-renewal (CSC marker expression, sphere-forming ability) and tumor-initiating capacity was examined in CSCs derived from A2780 human ovarian cancer cell line. JNK inhibition was achieved either pharmacologically or genetically by use of RNA interference. Results: Both pharmacological and genetic targeting of JNK resulted in loss of self-renewal and tumor-initiating capacity of A2780 CSCs. Conclusion: Our findings demonstrate, to our knowledge for the first time, that JNK has a pivotal role in the maintenance of ovarian CSCs. Citation Format: Manabu Seino, Masashi Okada, Keita Shibuya, Shizuka Seino, Shuhei Suzuki, Hiroyuki Takeda, Tsuyoshi Ohta, Hirohisa Kurachi, Kiyoshi Ito, Satoru Nagase, Chifumi Kitanaka. Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2228. doi:10.1158/1538-7445.AM2015-2228
Assessment of Hematologic and Visceral Parameters in Patients with Type 1 Gaucher Disease in Spain: An Epidemiological Study Using the Therapeutic Goals MAP (Monitor, Action and Progress) Tool®
Authors: Pilar Giraldo, Jordi Perez, Ramiro Núñez, Rafael Fernandez de la Puebla, Elisa Luño, Salvador Saura, Juan Carlos Bureo, Javier de la Serna, Sylvia Plaza, Víctor Navas
Journal: Blood (2014)
Dose Changing and Discontinuation of Imatinib In Patients Affected by Philadelphia Positive Chronic Myeloid Leukemia: a Longitudinal Analysis, a Single Centre Experience.
Authors: Serena Merante, Cristiana Pascutto, Ester Orlandi, Lara Pochintesta, Marina Boni, Celeste Calvello, Barbara Rocca, Paolo Bernasconi, Mario Lazzarino
Journal: Blood (2010)
Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Authors: Aneel Paulus, Pooja Advani, Betsy R. Laplant, Sharoon Akhtar, Taimur Sher, Candido E. Rivera, James M. Foran, Vivek Roy, Gerardo Colon-Otero, Sikander Ailawadhi, Asher Alban Chanan-Khan
Journal: Blood (2015)
P0780 : Deep sequencing analyses in HCV genotype 1-infected patients treated with simeprevir plus sofosbuvir with/without ribavirin in the cosmos study
Authors: B. Fevery, K. Thys, E. Van Rossem, T. Verbinnen, G. Picchio, J. Aerssens, S. De Meyer, M. Beumont, D. Kurland, O. Lenz
Journal: Journal of Hepatology (2015)
Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).
Authors: Varant Arzoumanian, Bart Barlogie, Mauricio Pineda-Roman, Klaus Hollmig, Elias Anaissie, Maurizio Zangari, Somashekar Krishna, Eilas Kiwan, Guido Tricot, Abid Mohiuddin, Frits van Rhee
Journal: Blood (2006)
PWE-066 Impact of A Capsule Endoscopy Service on The Management of Iron Deficiency Anaemia
Authors: S Sartain, N Zuhra, D Lloyd
Journal: Gut (2016)

<h3>Introduction</h3> Capsule endoscopy (CE) is increasingly being used to investigate iron deficiency anaemia (IDA) when bi-directional endoscopy does not find a cause although current guidelines do not recommend routine small intestinal investigation unless symptoms or recurrent/refractory IDA.<sup>1</sup> The aim of this study was to review the use of CE in the investigation of IDA over a two year period in a medium sized DGH following the creation of a new CE service. <h3>Methods</h3> Electronic records of all patients undergoing CE between 1<sup>st</sup> April 2013 and 31<sup>st</sup> March 2015 were reviewed. Indication for CE was recorded along with the result of the investigation. Clinic letters were reviewed to assess the impact of CE on patient management. <h3>Results</h3> Over the study period 97 CE procedures were performed. Fifty (52%) procedures were performed to investigate IDA, 34 (35%) for investigation of possible or known Crohn’s disease; 4 (4%) for polyposis and 9 (9%) for other indications. Of the 50 CE procedures for IDA, 18 (36%) showed abnormalities in the small bowel; these included polyps (28%), vascular lesions (33%) and ulcers (28%). No malignancy was found over the 2 year period although one large (3 cm) polyp exhibited high grade dysplasia. Thirteen procedures (26%) showed gastroduodenal pathology but no small bowel abnormality. There was no difference between the mean ages of patients with normal compared to abnormal small bowel CE findings (56.9 years old vs 57.6 years old). In 8 of the 18 cases (44%) where small bowel abnormalities were found there was a subsequent change in patient management; this included surgery to remove polyps, endoscopic treatment of vascular lesions and medication changes. Thirty-eight patients (76%) were discharged from clinical follow up following CE with advice to continue long-term iron supplementation; this included 8 patients with abnormalities seen at CE. <h3>Conclusion</h3> Over a third of patients undergoing CE to investigate IDA were found to have small bowel pathology. However less than half of these findings resulted in significant management changes. In total CE findings altered clinical management in only 16% of patients although it did allow 76% of patients to be discharged from further clinical follow-up. Clincal factors such as age did not appear to predict the presence of small bowel pathology. As a result, the role and timing of CE in the investigation of IDA remains uncertain. <h3>Reference</h3> 1 Guidelines for the management of iron deficiency anaemia. Goddard, <i>et al</i>. on behalf of the British Society of Gastroenterology 2011. <h3>Disclosure of Interest</h3> None Declared
S-1/oxaliplatin/irinotecan (SOXIRI) for advanced unresectable pancreatic cancer : a dose-finding study
Authors: Jun Okazaki, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Masako Kimura, Koichi Okamoto, Naoki Muguruma, Tetsuji Takayama
Journal: Annals of Oncology (2015)
PWE-001 Transcutaneous Cervical Vagal Nerve Stimulation Exerts an anti-TNF-Alpha Effect in Healthy Humans: Abstract PWE-001 Table 1
Authors: C Brock, B Brock, HJ Moller, AM Drewes, AD Farmer
Journal: Gut (2016)

<h3>Introduction</h3> The vagus nerve is the main neural substrate of the parasympathetic nervous system and has a role in modulating inflammation through the cholinergic anti-inflammatory pathway, via inhibition of the production of pro-inflammatory cytokines at the level of both the spleen and the intestinal muscularis. Animal studies have demonstrated that in vagotomised mice, electrical vagal nerve stimulation (VNS), applied distal to the severance, ameliorates the pro-inflammatory cytokine response to lipopolysaccharide. The cervical vagus nerve is located directly under the skin, making it a suitable target for transcutaneous non-invasive VNS (n-VNS). In this pilot study, we sought to evaluate the effect of non- n-VNS on pro-inflammatory cytokines and cardiometrically derived autonomic parameters in humans. <h3>Methods</h3> In healthy volunteers, heart rate, blood pressure and validated sympathetic, (cardiac sympathetic index) and vagal, (cardiac vagal tone (CVT)) indices were measured directly before, and 24 hours after, 2 minutes of n-VNS applied bilaterally. Venous blood was also drawn and assayed for pro-inflammatory cytokines (tumour necrosis factor-alpha (TNF-a) and interferon-gamma (IFN-g)) and the anti-inflammatory cytokine (interleukin-10) directly prior to, and 24 hours after n-VNS. <h3>Results</h3> 20 healthy volunteers (13 females, median age 34 years, range 23–55) all tolerated the n-VNS. Table 1 details the changes in the recorded parameters. There was a negative correlation between change in CVT and change TNF-a (r<sub>s</sub> = 0.45, p &lt; 0.05). <h3>Conclusion</h3> These results, for the first time in humans, provide preliminary evidence for an anti-TNF-a in response to n-VNS, potentially mediated by an increase cardiac vagal tone. These data, warrant further investigation in immune mediated inflammatory disorders such as those with inflammatory bowel disease. <h3>Disclosure of Interest</h3> None Declared
Efficacy and Feasibility of High-Dose Cytarabine Plus Idarubicin and Amifostine As Induction Schedule: A Prospective Observational Study of 100 AML Elderly Fit Patients
Authors: Debora Capelli, Martina Chiarucci, Francesco Saraceni, Antonella Poloni, Mauro Montanari, Massimo Offidani, Serena Rupoli, Anna Rita Scortechini, Guido Gini, Ilaria Scortechini, Pietro Leoni, Attilio Olivieri
Journal: Blood (2012)
Peripheral Blood Stem Cells Vs Bone Marrow: Stem Cell Source Comparison for Patients Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving an Allogeneic Stem Cell Transplantation from a 10/10 Matched Donor. Study from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)
Authors: Aurélie Ravinet, Aurélie Cabrespine, Gerard Socie, Noel Milpied, Ibrahim Yakoub-Agha, Stephanie Nguyen, Mauricette Michallet, Emilie Lemasle, Felipe Suarez, Natacha Maillard, Regis Peffault de Latour, Jacques-Olivier Bay
Journal: Blood (2014)
Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study
Authors: Patrick J Hanley, Caridad Martinez, Kathryn Leung, Barbara Savoldo, Gianpietro Dotti, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop, Robert A. Krance, Elizabeth J Shpall, Catherine M. Bollard
Journal: Blood (2012)
Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.
Authors: Miguel A. Sanz, Pau Montesinos, Edo Vellenga, Chelo Rayon, Ricardo Parody, Javier de la Serna, Juan Bergua, Angel Leon, Silvia Negri, Concha Rivas, Salut Brunet, Marcos Gonzalez, Jordi Esteve, Bob Lowenberg
Journal: Blood (2007)
PWE-130 Glasgow Blatchford Score (GBS) Identifies The Likelihood of Endoscopic Intervention Required – A Retrospective Study in A District Hospital
Authors: C Kong, S Murphy, M Moran, W Jafar
Journal: Gut (2016)

<h3>Introduction</h3> Upper GI bleeding (UGIB) is a common presentation to the emergency department.<sup>1</sup> Studies assessing the effectiveness of the Glasgow Blatchford Score (GBS) as a risk stratification tool are well documented in the literature. National Institute of Clinical Excellence (NICE) recommends that all patients admitted with suspected UGIB require a GBS score. This study evaluated the effectiveness of the GBS in predicting the need for endoscopic therapy. It also evaluated whether there was any correlation between the GBS with re-bleeding rates and 30 day mortality. <h3>Methods</h3> Electronic UGIB requests between January to July 2015 were evaluated retrospectively. Patients who were deemed medically fit for the procedure and underwent a gastroscopy as an in-patient were included in this study. Patients deemed medically unfit for a gastroscopy or were discharged prior to in-patient gastroscopy being performed were excluded from the study. The OGD reports were subsequently retrieved from electronic endoscopy reporting system “Unisoft” and the GBS was retrieved from the electronic request system. The re-bleeding rate and 30 day mortality were evaluated from the review of the electronic patient records. The data collected was entered onto Microsoft Excel 2010 spreadsheet and a chi-square test was applied. <h3>Results</h3> There were a total of 182 requests for urgent in-patient gastroscopy. 25 patients were excluded from the study - 3 were medically unfit for OGD on arrival, 3 unable to intubate, 1 request was later deemed not required, 1 was changed to outpatients and 17 no OGD reports could be retrieved from Unisoft. The remaining 157 underwent urgent in-patient gastroscopy. Age distribution ranged from 22 to 103 with mean age of 63. 90 patients were male (57%) and 67 were female (43%). Of the 157 patients, 48 (31%) required endoscopic intervention compared to 109 (69%) who did not. Of the 48 patients that required endoscopic intervention, 8 scored GBS &lt; 6 and 40 had GBS ≥ 6. The correlation between GBS and the need for endoscopic intervention was found to be statistically significant (p &lt; 0.001). Of the 157 patients, the re-bleeding rate was 1.8% (n = 3) during the same hospital admission and the 30 day mortality rate of 5.7% (n = 9). From the re-bleeding group, the mortality rate was 33% (n = 1). No statistical significance between GBS with re-bleeding rates (p = 0.17) and mortality (p = 0.33) was found. <h3>Conclusion</h3> This study identified that a GBS ≥ 6 significantly correlates with the likelihood of requiring endoscopic intervention as compared to a GBS &lt; 6. However, the GBS did not correlate with in-patient re-bleeding rate and 30 day mortality rate. <h3>Reference</h3> 1 Longstreth GF. Epidemiology of hospitalisation for acute upper GI haemorrhage: a population-based study. <i>Am J Gastroenterol</i> 1995;<b>90</b>:206. <h3>Disclosure of Interest</h3> None Declared
Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 - mTOR Pathway
Authors: Emilia Bialopiotrowicz, Patryk Gorniak, Maciej Szydlowski, Tomasz Sewastianik, Przemyslaw Kiliszek, Anna Polak, Ewa Jablonska, Bozena Katarzyna Budziszewska, Bartosz Pula, Maja Wasylecka, Katarzyna Borg, Hanna Makuch-Lasica, Grazyna Nowak, Ewa Lech-Maranda, Krzysztof Warzocha, Wojciech Czardybon, Michal Galezowski, Renata Windak, Krzysztof Brzozka, Przemyslaw Juszczynski
Journal: Blood (2015)
Myelodysplastic Syndrome (MDS) and Myeloproliferative Disease (MPD) in Children: A Prospective Registration of 222 Cases
Authors: Shinsuke Hirabayashi, Atsushi Manabe, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Atsuko Masunaga, Ayami Yoshimi, Masafumi Ito, Akira Kikuchi, Kohichiro Tsuji, Akira Ohara, Seiji Kojima, Tatsutoshi Nakahata
Journal: Blood (2008)
Clonal Cells Detected by Conventional Cytogenetic Analysis Correlates with Bone Marrow Blast Percentage and Progression Free Survival Into Acute Leukemia In Myelodysplastic Syndromes
Authors: Miyoung Kim, Cha Ja She, Sang Mee Hwang, Sung-Soo Yoon, Byoung Kook Kim, Dong Soon Lee
Journal: Blood (2010)
NIR-Laser-Controlled Drug Release from DOX/IR-780-Loaded Temperature-Sensitive-Liposomes for Chemo-Photothermal Synergistic Tumor Therapy
Authors: Fei Yan, Wanlu Duan, Yekuo Li, Hao Wu, Yuli Zhou, Min Pan, Hongmei Liu, Xin Liu, Hairong Zheng
Journal: Theranostics (2016)

NIR laser-induced photothermal therapy (PTT) through near-infrared agents has demonstrated the great potential in solid tumor ablation.However, the nonuniform heat distribution over tumors from PTT makes it insufficient to kill all tumor cells, resulting in tumor recurrence and inferior outcomes.To improve the tumor treatment efficacy, it is highly desirable to develop the combinational treatment of PTT with other modalities, especially with chemotherapeutic agents.Here we report a smart DOX/IR-780-loaded temperature-sensitive-liposome (DITSL) which can achieve NIR-laser-controlled drug release for chemo-photothermal synergistic tumor therapy.In this system, the liposoluble IR-780 was incorporated into the temperature-sensitive lipid bilayer and the soluble chemotherapeutic doxorubicin (DOX) was encapsulated in the hydrophilic core.The resulting DITSL is proved to be physiologically stable and can provide a fast and laser irradiation-controllable DOX release in the PBS and cellular conditions.We further employed this nanoparticle for tumor treatment, demonstrating significantly higher tumor inhibition efficacy than that of DOX-loaded temperature-sensitive-liposome (DTSL) or IR780-loaded temperature-sensitive-liposome (ITSL) in the in vitro cells and in vivo animals.Histological analysis further revealed much more apoptotic cells, confirming the advantageous anti-tumor effect of DITSL over DTSL or ITSL.Our study provides a promising strategy to realize chemo-photothermal synergistic combination therapy for breast tumors.
Human Placenta-Derived Adherent Stem Cells Prevent Bone Loss and Stimulate Bone Formation in Myelomatous Bones, and Suppress Growth of Primary Multiple Myeloma
Authors: Xin Li, Wen Ling, Angela Pennisi, Jianmei Chen, Sharmin Khan, Mohammad Heidaran, Herbert Faleck, Robert Hariri, John Shaughnessy, Frits van Rhee, Joshua Epstein, Bart Barlogie, Shmuel Yaccoby
Journal: Blood (2008)
Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes
Authors: Erika Dosekova, Jaroslav Filip, Tomas Bertok, Peter Both, Peter Kasak, Jan Tkac
Journal: Medicinal Research Reviews (2016)

Abstract This review comprehensively covers the most recent achievements (from 2013) in the successful integration of nanomaterials in the field of glycomics. The first part of the paper addresses the beneficial properties of nanomaterials for the construction of biosensors, bioanalytical devices, and protocols for the detection of various analytes, including viruses and whole cells, together with their key characteristics. The second part of the review focuses on the application of nanomaterials integrated with glycans for various biomedical applications, that is, vaccines against viral and bacterial infections and cancer cells, as therapeutic agents, for in vivo imaging and nuclear magnetic resonance imaging, and for selective drug delivery. The final part of the review describes various ways in which glycan enrichment can be effectively done using nanomaterials, molecularly imprinted polymers with polymer thickness controlled at the nanoscale, with a subsequent analysis of glycans by mass spectrometry. A short section describing an active glycoprofiling by microengines (microrockets) is covered as well.
A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation
Authors: Christof Scheid, Donna Reece, Meral Beksac, Andrew Spencer, Natalie Callander, Pieter Sonneveld, Ghulam Kalimi, Can Cai, Michael Shi, Jeffrey W. Scott, A. Keith Stewart
Journal: Blood (2012)
Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients
Authors: Josh Levitsky, Elizabeth C Verna, Jacqueline G O'Leary, Natalie H Bzowej, Dilip K Moonka, Robert H Hyland, Sarah Arterburn, Hadas Dvory-Sobol, Diana M Brainard, John G McHutchison, Norah A Terrault
Journal: New England Journal of Medicine (2016)

In this study of 16 patients with chronic HCV genotype 1 infection who were undergoing liver transplantation from an HCV-negative donor, a 4-week course of once-daily ledipasvir–sofosbuvir achieved a sustained virologic response in 14 of the 15 patients who completed treatment.
Late Platelets Recovery after Autografting (ASCT) in Patients with Acute Myeloid Leukemia (AML) Is A Prognostically Favourable Factor for Long-Term Remission
Authors: A. M. Carella, G Catania, R Varaldo, S Nati, A Congiu, R Vimercati, E Rossi, M Spriano
Journal: Blood (2008)
Prolonged Hypogammaglobulinemia After Rituximab Therapy for Post-Transplant EBV-Lymphoproliferative Disorder Following Hematopoietic Stem Cell Transplantation in Pediatric Patients
Authors: Claire Pluchart, Brigitte Lescoeur, Valérie Guérin, Frédérique Duquesne, Elisa Seror, Béatrice Pédron, Karima Yakouben, Marie Ouachee, Andre Baruchel, Ghislaine Sterkers, Jean-Hugues Dalle
Journal: Blood (2012)